The ketogenic diet, characterized by its elevated fat content and reduced carbohydrate intake composition, has garnered interest due to its potential benefits on mental health disorders and influence in health risk. Early research suggests that, the ketogenic diet may have therapeutic effects on conditions such as depression, anxiety, and bipolar disorder, although further research is required to validate these discoveries. One suggested reason is the diet's capacity to decrease oxidative stress, which is linked to the underlying causes of several mental health issues. The ketogenic diet is thought to alter the brain's energetic matrix, leading to changes in neurotransmitter function and brain metabolism. Understanding the brain effects of the ketogenic diet could provide valuable insights into its potential as an adjunctive therapy for mental illness. Early published reviews on ketogenic diets for mental illness often overlooked the intricate relationship between diet and mental health, focusing more on traditional pharmacological treatments. There is a gap in the existing evidence on the precise impact of ketogenic diets on mental health issues, highlighting the need for a comprehensive review in this area. This article comprehensively covers the relationship between ketogenic diets and mental illness, exploring the potential benefits and side effects. It discusses how ketogenic diets may influence oxidative stress in mental health disorders and examines their effects on the brain's energetic matrix. The article also addresses the benefits of ketogenic diets for mental health and highlights the potential side effects of ketogenic therapies. This review addresses previous lacunas by focusing on the specific effects of ketogenic diets on mental health disorders. It is timely and relevant in light of the increasing interest in alternative treatments for mental illness and health risk, providing valuable insights into the potential role of ketogenic diets in mental health care.

1. Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. Diet modulates brain network stability, a biomarker for brain aging, in young adults. Proc Natl Acad Sci U S A. 2020;117:6170–7. [PubMed: 32127481]
2. Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology. 2003;61:1789–91. [PubMed: 14694049]
3. Marosi K, Kim SW, Moehl K, Scheibye-Knudsen M, Cheng A, Cutler R, et al. 3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons. J Neurochem. 2016;139:769–81. [PubMed: 27739595]
4. Lopresti AL, Jacka FN. Diet and bipolar disorder: A review of its relationship and potential therapeutic mechanisms of action. J Altern Complement Med. 2015;21:733–9. [PubMed: 26348597]
5. Wolniczak, I., Cáceres-DelAguila, J.A., Maguiña, J.L., Bernabe-Ortiz, A., 2017. Fruits and vegetables consumption and depressive symptoms: A population-based study in Peru. PLoS One. 12(10), e0186379.
6. Bauer, I.E., Gálvez, J.F., Hamilton, J.E., Balanzá-Martínez, V., Zunta-Soares, G.B., Soares, J.C., Meyer, T.D., 2016. Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: A systematic review. J. Psychiatr. Res. 74, 1-7.
7. Sarris, J., Logan, A.C., Akbaraly, T.N., Amminger, P.G., Balanzá-Martínez, V.,Freeman, M.P., Hibbeln, J., Matsuoka, Y., Mischoulon, D., Mizoue, T., Nanri, A.,Nishi, D., Parletta, N., Ramsey, D., Rucklidge, J.J., Sanchez-Villegas, A., Scholey A.,Su K.P., Jacka, F.N., 2015. International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. World Psychiatry. 14, 370-1.
8. Martin K, Jackson CF, Levy RG, Cooper PN. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016; 2: Cd001903.
9. Freeman JM, Kossoff EH. Ketosis and the ketogenic diet, 2010: Advances in treating epilepsy and other disorders. Adv Pediatrics. 2010; 57: 315-329.
10. Kessler, R.C., Bromet, E.J., 2013. The epidemiology of depression across cultures. Annu. Rev. Public Health. 34, 119–138.
11. Merikangas, K.R., Cui, L., Kattan, G., Carlson, G.A., Youngstrom, E.A., Angst, J.,2012. Mania with and without depression in a community sample of US adolescents. Arch. Gen. Psychiatry. 69, 943-51.
12. Moreira, A.L.R., Van Meter, A., Genzlinger, J., Youngstrom, E.A. Review and Meta-Analysis of Epidemiologic Studies of Adult Bipolar Disorder. J Clin Psychiatry. 2017;78: e1259-e1269.
13. Judd, L.L., Akiskal, H.S., Schettler, P.J., Coryell, W., Endicott, J., Maser, J.D., Solomon, D.A., Leon, A.C., Keller, M.B., 2003. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch

Gen Psychiatry 60, 261-9.

1. Woo, Y.S., Seo, H.J., McIntyre, R.S., Bahk, W.M., 2016. Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review. Int J Mol Sci. 17, pii: E80
2. McIntyre, R.S., Soczynska, J.K., Konarski, J.Z., Woldeyohannes, H.O., Law, C.W., Miranda, A., Fulgosi, D., Kennedy, S.H., 2007. Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? Ann. Clin. Psychiatry. 19, 257-64.
3. Subramaniapillai, M., McIntyre, R.S., 2017. A review of the neurobiology of obesity and the available pharmacotherapies. CNS Spectr. 22, 29-38.
4. Czepielewski, L., Daruy Filho, L., Brietzke, E., Grassi-Oliveira, R., 2013. Bipolar disorder and metabolic syndrome: a systematic review. Rev. Bras. Psiquiatr. 35, 88-93.
5. McIntyre, R.S., Rasgon, N.L., Kemp, D.E., Nguyen, H.T., Law, C.W., Taylor, V.H., Woldeyohannes, H.O., Alsuwaidan, M.T., Soczynska, J.K., Kim, B., Lourenco, M.T., Kahn, L.S., Goldstein, B.I., 2009. Metabolic syndrome and major depressive disorder:co-occurrence and pathophysiologic overlap. Curr. Diab. Rep. 9, 51-9
6. Cha, D.S., Best, M.W., Bowie, C.R., Gallaugher, L.A., Woldeyohannes, H.O.,Soczynska, J.K., Lewis, G., MacQueen, G., Sahakian, B.J., Kennedy, S.H., Lui, J.P.,Mansur, R.B., McIntyre, R.S., 2017. A randomized, double-blind, placebo-controlled,
7. crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. J Affect Disord. 210, 57-65.
8. Mansur, R.B., Ahmed, J., Cha, D.S., Woldeyohannes, H.O., Subramaniapillai, M.,Lovshin, J., Lee, J.G., Lee, J.H., Brietzke, E., Reininghaus, E.Z., Sim, K., Vinberg, M.,Rasgon, N., Hajek, T., McIntyre, R.S., 2017. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J. Affect. Disord. 207, 114-120.
9. Norwitz NG, Dalai SS, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020;27:269–74.
10. Morris G, Puri BK, Carvalho A, Maes M, Berk M, Ruusunen A, et al. Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought? Int J Neuropsychopharmacol. 2020;23:366–84.
11. Antal B, McMahon LP, Sultan SF, Lithen A, Wexler DJ, Dickerson B, et al. Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses. Elife. 2022 May 24;11:e73138.
12. Watson KT, Simard JF, Henderson VW, Nutkiewicz L, Lamers F, Rasgon N, et al. Association of Insulin Resistance with Depression Severity and Remission Status: Defining a Metabolic Endophenotype of Depression. JAMA Psychiatry. 2021;78:439–41.
13. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902–7.
14. Van Eersel MEA, Joosten H, Gansevoort RT, Dullaart RPF, Slaets JPJ, Izaks GJ. The interaction of age and type 2 diabetes on executive function and memory in persons aged 35 years or older. PLoS One. 2013;8:e82991
15. Brosch K, Stein F, Schmitt S, Pfarr J-K, Ringwald KG, Thomas-Odenthal F, et al. Reduced hippocampal gray matter volume is a common feature of patients with major depression, bipolar disorder, and schizophrenia spectrum disorders. Mol Psychiatry. 2022 Jul 15. doi: 10.1038/s41380-022-01687-4
16. Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: A population-based analysis. Epilepsia. 2007; 48: 2336-2344.
17. Brietzke E, Mansur RB, Subramaniapillai M, Balanzá-Martínez V, Vinberg M, González-Pinto A, et al. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018;94:11–6. [PubMed: 30075165]
18. Kraeuter AK, Phillips R, Sarnyai Z. Ketogenic therapy in neurodegenerative and psychiatric disorders: From mice to men. Prog Neuro-Psychopharmacol Biol Psychiatry. 2020;101:109913.
19. McDonald TJW, Cervenka MC. Ketogenic Diets for Adult Neurological Disorders. Neurotherapeutics. 2018;15:1018–31. [PubMed: 30225789]
20. Sethi S, Wakeham D, Ketter T, Hooshmand F, Bjornstad J, Richards B, Westman E, Krauss RM, Saslow L. Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial. Psychiatry research. 2024 May 1;335:115866.
21. Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med. 2015; 13: 68.
22. Villa RF, Ferrari F, Bagini L, Gorini A, Brunello N, Tascedda F. Mitochondrial energy metabolism of rat hippocampus after treatment with the antidepressants desipramine and fluoxetine. Neuropharmacology. 2017; 121: 30-38.
23. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014; 29: 19-36.
24. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012; 135: 886-899.
25. Prolo C, Alvarez MN, Radi R. Peroxynitrite, a potent macrophage-derived oxidizing cytotoxin to combat invading pathogens. BioFactors (Oxford, England). 2014; 40: 215-225.
26. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 2010; 49: 1603-1616.
27. Ortiz GG, Pacheco-Moises FP, Bitzer-Quintero OK, Ramirez-Anguiano AC, Flores-Alvarado LJ, Ramirez-Ramirez V, et al. Immunology and oxidative stress in multiple sclerosis: Clinical and basic approach. Clin Dev Immunol. 2013; 2013: 708659.Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;

10: 217-224.

1. Steel CD, Breving K, Tavakoli S, Kim WK, Sanford LD, Ciavarra RP. Role of peripheral immune response in microglia activation and regulation of brain chemokine and proinflammatory cytokine responses induced during VSV encephalitis. J Neuroimmunol. 2014; 267: 50-60.
2. Morris G, Maes M. Oxidative and nitrosative stress and immune-inflammatory pathways in patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). Curr Neuropharmacol. 2014; 12: 168-185.
3. Morris G, Maes M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab Brain Dis. 2013; 28: 523-540.
4. Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003; 5: 417-418.
5. Heshmati M, Russo SJ. Anhedonia and the brain reward circuitry in depression. Curr Behav Neurosci Rep. 2015; 2: 146-153.
6. Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH. Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS Neurosci Ther. 2018; 24: 615-623.
7. Cuthbert BN, Kozak MJ. Constructing constructs for psychopathology: The NIMH research domain criteria. J Abnorm Psychol. 2013; 122: 928-937.
8. Subramaniapillai M, McIntyre RS. A review of the neurobiology of obesity and the available pharmacotherapies. CNS Spectr. 2017; 22: 29-38.
9. Peterman MG. Ketogenic diet in treatment of epilepsy. The Journal of Nervous and Mental Disease. 1924 Oct 1;60(4):413.
10. Martin, K., Jackson, C.F., Levy, R.G., Cooper, P.N., 2016. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst. Rev. 2, CD001903
11. Bostock, E.C., Kirkby, K.C., Taylor, B.V., 2017. The Current Status of the Ketogenic Diet in Psychiatry. Front Psychiatry. 8, 43
12. Pinto A, Bonucci A, Maggi E, Corsi M, Businaro R. Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer’s disease. Antioxidants. 2018 May;7(5):63.
13. Phelps, J.R., Siemers, S.V., El-Mallakh, R.S., 2013. The ketogenic diet for type II bipolar disorder. Neurocase 19, 423-6
14. Moylan, S., Maes, M., Wray, N.R., Berk, M., 2013. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry. 18, 595-606.
15. Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yücel, M., Gama, C.S., Dodd, S., Dean, B., Magalhães, P.V., Amminger, P., McGorry, P., Malhi, G.S., 2011. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35, 804-17.
16. Martinez-Cengotitabengoa, M., MacDowell, K.S., Alberich, S., Diaz, F.J., Garcia- Bueno, B., Rodriguez-Jimenez, R., Bioque, M., Berrocoso, E., Parellada, M., Lobo, A.,Saiz, P.A., Matute, C., Bernardo, M., Gonzalez-Pinto, A., Leza, J.C.; FLAMM-PEPs,2016. BDNF and NGF Signalling in Early Phases of Psychosis: Relationship with Inflammation and Response to Antipsychotics After 1 Year. Schizophr Bull. 42, 142-51
17. Koppel, S.J., Swerdlow, R.H., 2017. Neuroketotherapeutics: A modern review of a century-old therapy. Neurochem. Int. S0197-0186, 30227-9.

1. Genzer, Y., Dadon, M., Burg, C., Chapnik, N., Froy, O., 2016. Effect of dietary fat and the circadian clock on the expression of brain-derived neurotrophic factor (BDNF). Mol. Cell Endocrinol. 430, 49-55.
2. Puchowicz, M.A., Xu, K., Sun, X., Ivy, A., Emancipator, D., LaManna, J.C., 2007. Diet-induced ketosis increases capillary density without altered blood flow in rat brain.Am J Physiol Endocrinol. Metab. 292, E1607-15
3. Hartman, A.L., Gasior, M., Vining, E.P., Rogawski, M.A., 2007. The neuropharmacology of the ketogenic diet. Pediatr. Neurol. 36, 281-92
4. Miller VJ, Villamena FA, Volek JS. Nutritional ketosis and mitohormesis: Potential implications for mitochondrial function and human health. J Nutr Metab. 2018 Feb 11;2018:5157645.
5. McClernon FJ, Yancy WS, Eberstein JA, Atkins RC, Westman EC. The effects of a low-carbohydrate ketogenic diet and a low-fat diet on mood, hunger, and other self-reported symptoms. Obesity. 2007;15:182. [PubMed: 17228046]
6. Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10237–9.
7. Mohorko N, ?erneli?-Bizjak M, Poklar-Vatovec T, Grom G, Kenig S, Petelin A, et al. Weight loss, improved physical performance, cognitive function, eating behavior, and metabolic profile in a 12-week ketogenic diet in obese adults. Nutr Res. 2019;62:64–77.
8. El-Mallakh RS, Paskitti ME. The ketogenic diet may have mood-stabilizing properties. Med Hypotheses. 2001;57:724–6.
9. Cunnane SC, Courchesne-Loyer A, St-Pierre V, Vandenberghe C, Pierotti T, Fortier M, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann N Y Acad Sci. 2016;1367:12–20.
10. Veech RL. The therapeutic implications of ketone bodies: The effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fat Acids. 2004;70:309–19.
11. Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 1995;9:651–8.
12. Norwitz NG, Dalai SS, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020;27:269–74.
13. Health Virta. Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study, Available from: https://www.virtahealth.com/blog/virta-sustainable-health-improvements-5-year-diabetes-reversal-study. Accessed 2022 Aug 29
14. Athinarayanan SJ, Hallberg SJ, McKenzie AL, Lechner K, King S, McCarter JP, et al. Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:1–13.
15. Parry-Strong A, Wright-McNaughten M, Weatherall M, Hall RM, Coppell KJ, Barthow C, et al. Very low carbohydrate (ketogenic) diets in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2022 Aug 15. doi: 10.1111/dom.14837
16. Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav. 2010;19:575–9.
17. Cervenka MC, Patton K, Eloyan A, Henry B, Kossoff EH. The impact of the modified Atkins diet on lipid profiles in adults with epilepsy. Nutr Neurosci. 2016;19:131–7.
18. McDonald TJW, Cervenka MC. Ketogenic Diets for Adult Neurological Disorders. Neurotherapeutics. 2018;15:1018–31.
19. Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Jun 24;6(6):CD001903
20. Ye F, Li XJ, Jiang WL, Sun H-B, Liu J. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: A meta-analysis. J Clin Neurol. 2015;11:26–31
21. Cervenka MC, Henry BJ, Felton EA, Patton K, Kossoff EH. Establishing an Adult Epilepsy Diet Center: Experience, efficacy and challenges. Epilepsy Behav. 2016;58:61–8.
22. Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018;9:583–612
23. Leffler DA, Edwards-George J, Dennis M, Schuppan D, Cook F, Franko DL, et al. Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci. 2008;53:1573–81
24. Féart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues J-F, et al. Adherence to a mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302:638–48.
25. Paoli A, Bianco A, Damiani E, Bosco G. Ketogenic diet in neuromuscular and neurodegenerative diseases. BioMed Res Int. 2014; 2014: 474296
26. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007; 62: 427-433.
27. Holt EM, Steffen LM, Moran A, Basu S, Steinberger J, Ross JA, et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. JAm Diet Assoc. 2009; 109: 414-421.
28. Sampath A, Kossoff EH, Furth SL, Pyzik PL, Vining EP. Kidney stones and the ketogenic diet: Risk factors and prevention. J Child Neurol. 2007; 22: 375-378
29. Best T, Franz D, Gilbert D, Nelson D, Epstein M. Cardiac complications in pediatric patients on the ketogenic diet. Neurology. 2000; 54: 2328-2330.